Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Name: Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease
Published: 2023
License: Public Domain

RenJi Hospital · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

chronic-kidney-disease na obesity

obesity, chronic kidney diseases, chronic kidney disease, sodium glucose cotransporter 2 inhibitors (sglt2i), glucagon like peptide-1 receptor agonists (glp-1ra), interventional, na

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Related documents